HVTN 067

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-Boost Regimen, When Given to Healthy, Vaccinia-Naive, HIV-1-Uninfected Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), Epimmune, Bavarian Nordic, HIV Vaccine Trials Network (HVTN) April 26, 2007
EP-1233,MVA-mBN32 DNA CTL 21 + HTL 18 fused; MVA Gag, Pol, Vpr, Nef, Rev, Env
EP-1233 DNA
MVA-mBN32 Viral Vector - Pox
USA 108